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The rising cost of global healthcare provision and new approaches to managing disease are driving 30 
the development of low-cost biosensing modalities, such as label-free photonic methods based on 31 
dielectric resonances. Here, we use the combined sensing and imaging capability of a guided mode 32 
resonance (GMR) sensor to detect multiple biomarkers (troponin, procalcitonin and C-Reactive 33 
Protein) in parallel in undiluted urine samples. A key requirement of such a biosensor is the simple 34 
and direct functionalization with suitable antibodies to ensure the disease-specific detection of 35 
protein biomarkers. Here, antibodies were immobilized using a succinimidyl-[(N-36 
maleimidopropionamido)-hexaethyleneglycol] ester (SM(PEG)6) spacer. The polyethylene glycol 37 
(PEG) chemistry enables low detection limits of 10 pg mL-1 or better for all protein biomarkers, 38 
while minimizing non-specific binding compared to more commonly used strategies such as (3-39 
Aminopropyl)triethoxysilane (APTES) or dextran. Our approach supports the vision of a simple 40 
yet highly sensitive diagnostic platform that could be used for pre-screening patients for a wide 41 











1. Introduction  50 
Early recognition and targeted treatment of disease is an essential element of healthcare provision. 51 
Being able to detect multiple biomarkers in a single test is particularly desirable, as it allows for a 52 
more accurate and personalised diagnosis or for screening for a wide range of diseases in a single 53 
test. Conducting such a test in a clinical matrix is essential and doing so in urine is particularly 54 
desirable as the sample can be collected non-invasively, which is preferred by patients. The 55 
challenge of using urine as a sample matrix is that the concentration of biomarkers is typically low; 56 
the physiological concentration of many proteins is 3-4 orders of magnitude lower in urine than in 57 
blood plasma (Eamudomkarn et al., 2018), which presents a major challenge to the sensing 58 
modality. For example, the cardiac biomarker troponin needs to be detected at levels of 10-40  pg 59 
mL-1 in urine for the sensor to be clinically relevant (Tanislav et al., 2016; Upasham et al., 2018).   60 
Various sensor technologies have been developed to meet these demands, including 61 
electrochemical, calorimetric, piezoelectric, and optical biosensors (Kazemi-Darsanaki et al., 2013; 62 
Kenaan et al., 2016; Thakur and Ragavan, 2013; Thévenot et al., 2001). Biosensors based on optical 63 
transduction are particularly attractive as they offer high sensitivity, contact-free and simultaneous 64 
detection of multiple biomarkers. Furthermore, the refractive index sensitivity of photonic 65 
resonances can be exploited to enable label-free biomarker detection, further simplifying the 66 
diagnostic procedure. The diagnostic potential of resonant photonic sensors, such as those based 67 
on surface plasmon resonance (SPR), microring resonance or guided mode resonance (GMR) has 68 
already been demonstrated. While waveguide-based sensors such as microrings (Luchansky et al., 69 
2010) and bimodal waveguides (Herranz et al., 2017) are the most sensitive amongst these, they 70 
require accurate alignment strategies in order to couple the light into the waveguide which makes 71 




GMR-based biosensors means light can be coupled easily into the grating using a simple collimated 73 
beam. The key question is then whether the intrinsically low quality factor of the leaky mode 74 
approach prevents a sensor from achieving the high sensitivity required to detect disease 75 
biomarkers in urine? 76 
The GMR sensing modality was first proposed by Wang and Magnusson (Wang and Magnusson, 77 
1993), and demonstrated experimentally as fiber endface biosensor by Wawro (Wawro et al., 2000).  78 
Later, Cunningham et al. showed that the grating structure can be fabricated inexpensively by 79 
replica moulding or nanoimprint techniques (Cunningham, 2010). Recently, we introduced the 80 
chirped GMR approach (Triggs et al., 2017). The chirp translates spectral information into spatial 81 
position, so the refractive index change caused by molecular binding can be detected simply by 82 
imaging the spatial position of the optical resonance. This means that the bulky and expensive 83 
spectrometer typically required for monitoring the shift in optical resonance can be replaced with 84 
a simple, low cost camera. Here, we take this imaging capability one step further and demonstrate 85 
that multiple sensing areas can be monitored in parallel, thereby adding multiplexing capability 86 


















A GMR is a refractive index sensor that requires surface functionalization with a capture molecule, 102 
such as an antibody, to gain specificity. Limits of detection achieved so far using a functionalized 103 
chirped-GMR sensor are in the ng mL-1 range, which is comparable with other leaky-mode 104 
Fig. 1. Multiplexing capability of a chirped GMR sensor. a) Schematic diagram of the measurement 
setup showing the multiplexed chirped GMR consisting of four independent measurement channels. Three 
channels are functionalized with biomarker-specific antibodies, here C-reactive protein (CRP), troponin 
(TNNT1) and procalcitonin (PCT). The fourth channel is unfunctionalized and used as a reference to account 
for systemic drifts e.g. due to temperature. b) Field of view of the camera showing all 4 channels. Each 
channel contains two GMRs to provide redundancy and increase fidelity. c) The microfluidic channels are 




modalities, e.g. plasmonic nanoholes (145 pg mL-1) (Li et al., 2017). Nevertheless, in order to be 105 
truly competitive with conventional diagnostics based on the enzyme-linked immunoassay 106 
(ELISA), and to provide clinically relevant sensitivity, the sensor needs to demonstrate 1-10 pg 107 
mL-1 sensitivity. Here, we demonstrate performance at this level by introducing an improved 108 
functionalization protocol.  109 
The key requirement for any functionalization protocol is high affinity binding to a particular target 110 
molecule, coupled with the minimization of non-specific binding events which would otherwise 111 
reduce the detection specificity. The latter requirement of non-specific binding is often overlooked; 112 
many studies in the literature have been conducted with laboratory dilutions that avoid non-specific 113 
binding simply by the absence of competing agents instead of by optimizing the protocol for real 114 
sample matrices such as undiluted urine or blood. Furthermore, many protocols are carefully 115 
optimized for a specific antigen/antibody pair. However, achieving high performance for 116 
multiplexed detection without optimizing each assay is still a challenge.  117 
The functionalization of dielectric or silicon surfaces used in photonic biosensors typically employ 118 
silane chemistries to render the surface reactive against carboxylate or amine groups exposed on 119 
an antibody surface (Vashist, 2012). For example, (3-Aminopropyl)triethoxysilane (APTES) is 120 
commonly used to generate primary amine groups on the sensor surface to which the antibodies 121 
are crosslinked via exposed carboxylate groups using the EDC/NHS chemistry (1-Ethyl-3-(3-122 
dimethylaminopropyl)carbodiimide/N-hydroxysuccinimide, resulting in the formation of a stable 123 
amide bond. While simple and inexpensive, the amine coupling chemistry can lead to 124 
multimerization of the activated antibodies that may mask its binding sites and introduce 125 
conformational stress (Dixit et al., 2011; Stefansson et al., 2012), and lead to reduced specificity 126 




Moreover, the chain length of APTES is short resulting in steric hindrance that impedes antigen 128 
binding (Kim and Herr, 2013; Makaraviciute and Ramanaviciene, 2013). A longer, flexible spacer 129 
consisting of a hydrophilic, anti-fouling polymer is desirable in order to enable higher density 130 
immobilization of antibodies with steric freedom (Jönsson et al., 2008; Yakovleva et al., 2003). A 131 
common example of such a spacer is dextran, which provides a large volume of antibody binding 132 
sites because of its porous structure and its large molecular weight (Kim and Herr, 2013; Lee et al., 133 
2013). Although the dextran matrix provides the sensor surface with a large number of binding 134 
sites, many of these sites can also cause significant non-specific binding, which is clearly 135 
undesirable. 136 
Here, we exploit the commercially available SM(PEG)6 spacer (succinimidyl-[(N-137 
maleimidopropionamido)-hexaethyleneglycol] ester) as a crosslinker between the sensor surface 138 
and the antibody. PEG has previously been adopted to reduce steric hindrance, improve water 139 
solubility and reduce aggregation (Kim and Herr, 2013; Li et al., 2016; Nagasaki et al., 2007; 140 
Pochechueva et al., 2014; Weimer et al., 2000; Wen et al., 2009; Yuan et al., 2014). SM(PEG)6 is 141 
a sulfhydryl and amine reactive heterofunctional polyethylene glycol (PEG) with N-142 
hydroxysuccinimide (NHS) ester and maleimide groups at the termini. Maleimide terminated PEG 143 
is thiol-reactive which is used in our binding assay for bioconjugation with the sensor surface that 144 
has been thiolated using 3-Mercaptopropyl)trimethoxysilane (MPTS). This results in a surface 145 
functionalized with a monolayer of NHS esters which can form a covalent bond with free amines 146 
exposed on the antibody surface. We also note that the physical thickness of the SM(PEG)6 147 




nm (Drayton et al., 2019). We thus do not expect the SM(PEG)6 spacer to adversely affect the 149 






Fig. 2. Functionalization protocol using PEG as a spacer on a silicon nitride GMR. (1) 
Hydroxyl groups (OH) are introduced to the surface by piranha treatment. (2) Sulfhydryl groups 
are generated by (3-Mercaptopropyl)trimethoxysilane (MPTS) salinization for 7h. (3) SM(PEG)6 
crosslinkers are introduced to the sulfhydryl groups via the maleimide groups after incubation 
overnight in DMSO. (4) Antibody is introduced and immobilized on the PEGylated surface via its 
primary amine group to form an amide bond after 60 min of incubation. (5) Casein blocking buffer 
(1%) is added for ~30 min to block non-specific binding sites. (6) The Recombinant protein is 




2. Experimental section 156 
Sub-sections regarding materials, chirped GMR fabrication, microfluidics, channels fabrication, 157 
and functionalization protocols including EDC/Sulfo-NHS, SM(PEG)6, and Dextran chemistry are 158 
provided in the supplementary information file. 159 
3. Results 160 
3.1. Quartz crystal microbalance with dissipation (QCM-D) analysis 161 
We first used a quartz crystal microbalance with dissipation (QCM-D) using silicon dioxide quartz 162 
sensor to optimize the functionalization protocol using an antibody against Immunoglobulin G (IgG) 163 
(anti-IgG) as an exemplar (see experimental methods for detail). QCM-D is a well-established 164 
reference tool that provides quantitative data, so is ideally suited for process development. A clear 165 
binding curve is observed as the anti-IgG immobilizes on the PEG spacer Fig. 3a. Upon saturation, 166 
the surface is washed with PBS to remove unbound antibodies, followed by flushing with casein 167 
buffer (1%) to block any remaining non-specific binding sites. We observe negligible binding of 168 
casein suggesting that the PEG forms a densely packed, anti-fouling monolayer. Finally, IgG is 169 
introduced into the QCMD flow cell leading to a clear binding curve. For comparison, the protocol 170 
was repeated for surfaces functionalized with APTES and dextran (see methods section and Fig. 171 
S2a and Fig. S2b for more detail). The specific and non-specific binding for these surfaces in 172 
comparison to the PEG functionalized sensor is quantified in Fig. 3b and Table S1. The shift in 173 
resonant frequency upon exposure to anti-IgG is highest for PEG, indicating a greater density of 174 
surface immobilized antibodies. This is mirrored by the IgG binding (red bars). Importantly, the 175 
amount of non-specific binding is smallest for the PEG functionalized surface (using casein as an 176 
indicator for non-specific binding). Overall, PEG offers the highest specific and the lowest non-177 




surface (Fig. S2c and Fig. S2d), which is likely due to the minimization of steric hindrance coupled 179 
with the anti-fouling properties inherent to PEG monolayers. This combination of properties is 180 
critical for highly sensitive biomarker detection in a clinical matrix. 181 
 182 
Fig. 3c shows the pH-dependence of binding between IgG and surface immobilized anti-IgG for a 183 
pH range between 5.4 and 8.4, which highlights the best performance at near neutral pH (maximum 184 
at pH = 7.4), in agreement with the results reported in the literature (Barnes, 1966; Hughes-Jones 185 
Fig. 3. Quartz crystal microbalance with dissipation (QCM-D) analysis. (a) IgG binding assay 
employing SM(PEG)6 at pH = 7.4. (b) Comparison of the different functionalization protocols (APTES, 
Dextran and PEG) in terms of non-specific binding and in terms of frequency shift upon binding to IgG. 
Each point represents the mean ±SD of three replicates. (c) pH dependence on IgG binding. (d) IgG 





et al., 1964; Yang et al., 2017). Finally, we examined the binding performance as a function of IgG 186 
concentration at pH = 7.4 for concentrations between 10 ng mL-1 to 100 μg mL-1 and observe a 187 
clear binding Langmuir isotherm (Fig. S2d), which allows us to determine a dissociation constant 188 
KD of 5 nM (750 ng mL-1), in close agreement with published values (~4 nM) (Kuo and 189 
Lauffenburger, 1993; Strauch et al., 2014).  190 
3.2. Chirped guided mode resonance (GMR) analysis 191 
Following the QCMD control experiments, we applied the PEG protocol to the chirped GMR 192 
sensor. The calibration indicates that a 1µm shift in position corresponds to 1.67x10-4 refractive 193 
index units (RIU) (Triggs et al., 2017). Given the noise figure of 0.35 µm (Fig. S3), this corresponds 194 
to a limit of detection of 5.8x10-5 RIU. Note that the results in Fig. 4 were all obtained in undiluted 195 
human urine adjusted to pH = 7.4. The full measurement sequence is shown in Fig. 4. After 196 
introducing the SM(PEG)6 overnight to ensure the maximum coverage (Fig. S4), un-bound 197 
reagents are removed by a dimethyl sulfoxide (DMSO) wash, followed by drying with nitrogen 198 
gas. The surface is then exposed to PBS at pH = 7.4 to establish a baseline. Next, the antibodies 199 
are added (anti-IgG, anti-CRP, anti-PCT and anti-TNNT1) through the independent 200 
polydimethylsiloxane (PDMS) flow channels, followed by the casein blocker.  A clear binding 201 
curve is observed associated with immobilization of the antibodies on the sensor surface. Again, 202 




highlighting the density and anti-fouling properties of the PEG monolayer. Following antibody 204 
Fig. 4. Binding assay using PEGylated chirped GMR sensor. (a) Demonstration of binding assay 
conducted in urine (pH = 7.4), showing the shift in resonance position against time with each assay step. 
Each channel comprises a single antibody that is challenged with its associated, recombinant antigen. A 
clear binding curve is observed for each of the 4 proteins at a concentration of 10 pg mL-1, i.e. procalcitonin 
(PCT), C-reactive protein (CRP), troponion (TNNT1), and Immunoglobulin G (IgG). (b) Comparison of the 
maximum shift observed for the 4 proteins, for a concentration of 10 pg mL-1. Each point represents the 
mean ±SD of four replicates. The noise level value (3σ) is also indicated. (c) Controlled measurement, 
demonstrating that no binding is observed for mixture of TNNT1, CRP and PCT against an IgG antibody. 
(d) Similarly, no IgG binding is observed in the absence of a suitable antibody, demonstrating that the curves 




functionalization, the four channels were exposed to urine which leads to a shift in resonance due 205 
to the higher refractive index; we see a similar effect in a control experiment conducted with PBS 206 
and urine in the absence of antibody (Fig. S5). Later, we add urine spiked with a recombinant 207 
protein biomarker at a concentration of 10 pg mL-1 and see clear shifts for all channels. The urine 208 
pH was adjusted by adding a few microliters of a strong base (NaOH) to 45 ml of urine, thus the 209 
dilution factor is negligible. It is worth noting that the binding efficiency of each antigen-antibody 210 
pair depends on the pH of the medium. While it would be ideal to optimize the pH for each channel, 211 
this would complicate sample preparation and would not be possible in a multiplexed format, so 212 
would be undesirable for point-of-care applications. Despite these limitations, our results show an 213 
excellent sensitivity at a single pH-value for all 4 antibody-antigen pairs. 214 
IgG immunoassay is conducted in individual channel.  We also used a reference channel to 215 
minimize the influence of temperature variations and background noise, by subtracting from the 216 
measurement channel, see supporting information (Fig. S6).  Finally, a urine washing step is 217 
performed after the addition of biomarkers. No shift in the resonance position is observed, 218 
indicative of antibody-antigen binding rather than physisorption. Interestingly, these results are 219 
similar and within experimental error to those conducted in PBS rather than urine (Fig. S7), which 220 
again highlights the good surface coverage of the PEG and the suppression of non-specific binding. 221 
As urine typically contains a high level of salts, the ionic strength of the solution may impact on 222 
the weak non-covalent bond between antibody and antigen. We are therefore particularly pleased 223 
to note the high efficiency of the PEG-functionalised surface in terms of anchoring antibodies and 224 
enabling binding to their complementary antigens, even in a matrix of undiluted human urine. Fig. 225 
4b shows the resonant shifts observed for 10 pg mL-1 of the four protein biomarkers (0.47 µm 226 




respectively). Since the GMR is a refractive index sensor, one would expect that the magnitude of 228 
the resonant shift would increase with molecular weight. This trend is observed qualitatively, i.e. 229 
the smallest molecule (PCT, 13 kDa) produces the smallest shift, and IgG (150 kDa) the largest, 230 
although as expected the difference does not scale quantitatively with mass. Finally, we add urine 231 
spiked with IgG, TNNT1, and PCT at concentrations ranging from 10 pg mL-1 up to 1 µg mL-1, 232 
along with CRP at concentrations ranging from 1 pg mL-1 up to 1 µg mL-1 (Fig. S8). 233 
Further controlled experiments confirm that we observe specific interactions between the 234 
immobilized antibodies and the associated antigen rather than physisorption. Firstly, we observe 235 
no shift in resonance when a sensor surface functionalized with anti-IGG is challenged with urine 236 
spiked with a mixture of TNNT1, CRP and PCT (Fig. 4c). When the same surface is subsequently 237 
exposed to IgG at 100 ng mL-1, we observe a clear binding curve, highlighting that the antibody 238 
binding sites remain active following exposure to other proteins. Secondly, Fig. 4d shows a PEG 239 
functionalized but antibody-free surface exposed to IgG. No significant binding of IgG is observed. 240 
We therefore unambiguously demonstrate that the binding curves observed are due to the formation 241 
of an antibody-antigen complex.  242 
3.3. Comparison to previous results  243 
It is interesting to compare our result to competing approaches. Most notably, surface plasmon 244 
resonance (SPR) is considered by many as the gold standard for label-free sensing via photonic 245 
resonances. SPR-based biosensors have been reported that are capable of detecting protein 246 
biomarkers with a detection limit of 460 pg mL-1 in 1:1 diluted urine (Soler et al., 2016), and 140 247 
pg mL-1 in PBS (Li et al., 2017). This comparison clearly shows that the GMR technology is highly 248 




offers highly efficient and selective binding of antigens while suppressing non-specific binding. 250 
More importantly, the performance we quote is comparable to the typical detection limit quoted 251 
for an enzyme-linked immunoassay (ELISA), the laboratory gold standard, which is in the low pg 252 
mL-1 range (Sui et al., 2006). This means that the intrinsically simple and label-free GMR approach 253 
achieves the same performance as a fluorescent label-based ELISA that requires trained laboratory 254 
personnel, which is quite remarkable.  255 
4. Discussion 256 
We have exploited the combined sensing and imaging capability of a chirped guided mode 257 
resonance sensor to demonstrate label-free detection of multiple disease-relevant proteins in 258 
undiluted human urine. Specifically, we have demonstrated the detection of four protein 259 
biomarkers, all at a limit of detection of better than 10 pg mL-1. The high performance and ability 260 
to perform multiple tests in parallel is supported by the use of a SM(PEG)6 spacer layer in the 261 
functionalization protocol which introduces steric freedom and permits the immobilization of 262 
antibodies at high density while minimizing nonspecific binding. We have verified this 263 
performance against comparable protocols using APTES and dextran that are typically used for 264 
dielectric sensor surfaces and have shown improved performance. A comparison against other 265 
photonic sensor modalities is made more difficult by the fact that most published results only refer 266 
to laboratory dilutions, which avoid nonspecific binding by the absence of competing agents, while 267 
our results are achieved in undiluted human urine. Moreover, our sensor and photonic readout 268 
mechanism is intrinsically low-cost and does not require careful alignment or expensive 269 
components, which sets it further apart. In this regard, it is particularly surprising that our label-270 
free approach now achieves the same pg ml-1 performance as commercially available enzyme-271 




5. Conclusion 273 
In conclusion, the parallel detection of 4 clinically relevant biomarkers in human urine, all at 274 
concentrations of 10 pg ml-1 or below, demonstrates that the guided mode resonance (GMR) 275 
sensing modality, together with a highly efficient PEGylation process for immobilizing antibodies, 276 
offers a favorable combination of properties for the realization of low-cost, high performance 277 
biosensors suitable for evaluating clinical samples. The technology is intrinsically simple, yet it is 278 
essential to demonstrate similar performance as shown here also in a handheld format and in a 279 
clinical setting in order to prove its true value as a point-of-care tool. 280 
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